Techno Medica (6678) Fundamentals 2026 — P/E 13.4x, Revenue Analysis | SniperIQ
Techno Medica (6678) is a JP-listed Healthcare company in Medical - Devices with a market capitalization of ¥13.8B, trading at ¥2076.00 on the JPX. This SniperIQ fundamentals page covers Techno Medica's valuation (P/E 13.4x, P/B 1.0x), profitability (net margin 9.5%), revenue (¥11.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Techno Medica's market cap?
Techno Medica (6678) has a market capitalization of approximately ¥13.8B, trading at ¥2076.00 on the JPX. Market cap moves with the live share price.
What is Techno Medica's P/E ratio?
Techno Medica's trailing twelve-month P/E ratio is 13.4x, with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Techno Medica?
Techno Medica runs a net profit margin of 9.5%, a gross margin of 46.7%, and an operating margin of 14.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Techno Medica generate?
Techno Medica reported revenue of ¥11.2B for fiscal year 2025, with net income of ¥1.1B and earnings per share (EPS) of 155.28. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Techno Medica pay a dividend?
Techno Medica offers a trailing dividend yield of about 6.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Techno Medica financially healthy?
Techno Medica carries a debt-to-equity ratio of 0.00x and a current ratio of 5.09x, with a market beta of 0.24. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Techno Medica a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Techno Medica (6678) the key facts are: market cap ¥13.8B, P/E 13.4x, revenue ¥11.2B, 52-week range 1850-2787. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Techno Medica's full fundamentals live
Get Techno Medica's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.